Pushing forward in sarcoma with a new TCR targeting NY-ESO-1

A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.(1) is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.

Detalles Bibliográficos
Autores principales: Al-Marayaty, Rusul, Pollack, Seth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439265/
https://www.ncbi.nlm.nih.gov/pubmed/37586326
http://dx.doi.org/10.1016/j.xcrm.2023.101159
Descripción
Sumario:A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.(1) is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.

Ejemplares similares